News

ARS Pharmaceuticals Raises $55 Million in Series D Funding for Launch Preparations of Neffy™ (epinephrine nasal spray)

San Diego, Calif. – August 31, 2021 – ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, has closed on a Series D financing of $55 million led by SR One with participation from...

ARS Pharmaceuticals Strengthens Board of Directors with Appointment of Industry Leader and Innovator Brent Saunders

SAN DIEGO – May 13, 2021 – ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, today announced the appointment of biotech leader and visionary Brent Saunders to its Board of Directors. Mr. Saunders...

ARS Announces Acceptance of Market Authorization Application submission to European Medicines Agency for Neffy (ARS-1; epinephrine nasal spray)

SAN DIEGO, November 23, 2020 – ARS Pharmaceuticals (ARS) announced today that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) submission for review of NeffyTM (ARS-1; epinephrine nasal spray) an epinephrine nasal spray for the emergency treatment of severe allergic reactions, including anaphylaxis. This follows ARS’...

ARS Pharmaceuticals and Recordati Announce Exclusive License for the Rights in Europe and additional countries for NeffyTM (ARS-1; epinephrine nasal spray)

Agreement will give access to millions at risk for severe allergic reaction to new pain-free delivery method for epinephrine and will help in efforts to gain regulatory approval for ARS-1 (known as NeffyTM in the U.S.) around the world SAN DIEGO SEPTEMBER 22, 2020—ARS Pharmaceuticals (ARS) announced that it has...